Profile
From: WHO, 2015. Nigeria Malaria Profile. Geneva: World Health Organization. Available at: www.who.int
Epidemiological profile of Nigeria
| Population by malaria endemicity (000) | 2015 | % |
|---|---|---|
| High transmission (≥ 1 case per 1000 population) | 139 000 | 76 |
| Low transmission (0-1 cases per 1000 population) | 43 000 | 24 |
| Malaria free (0 cases) | 0 | 0 |
| Total | 182 200 |
| Parasites and vectors | |
|---|---|
| Major plasmodium species | P. falciparum (100%), P. vivax (0%) |
| Major anopheles species | An. gambiae, arabiensis, funestus, moucheti, melas, nili |
Intervention policies and strategies
| Intervention | WHO-recommended policy/strategy | Yes/no | Year adopted |
|---|---|---|---|
| ITN/LLIN |
ITNs/LLINs distributed free of charge ITNs/LLINs distributed to all age groups |
Yes Yes |
2001 2009 |
| IRS |
IRS is recommended DDT is used for IRS |
Yes No |
2007 - |
| IPT | IPT is used to prevent malaria during pregnancy | Yes | 2004 |
| Case management |
Patients of all ages should receive diagnostic test RDTs used at community level ACT is free for all ages in public sector Pre-referral treatment with recommended medicines Marketing authorization for all oral artemisinin-based monotherapies withdrawn |
Yes No Yes Yes Yes |
2010 - 2009 2006 2009 |
| Antimalarial policy | Type of medicine | Year adopted |
|---|---|---|
| First-line treatment of unconfirmed malaria | AL; AS+AQ | 2004 |
| First-line treatment of P.falciparum | AL; AS+AQ | 2004 |
| For treatment failure of P.falciparum | QN | 2004 |
| Treatment of severe malaria | AM; AS; QN | 2004 |
| Treatment of P.vivax | - | - |
Therapeutic efficacity tests (therapeutic or parasitological failure, %)
| Medicine | Year | No. of studies | Min. | Median | Max. | Follow-up |
| AL | 2005-2011 | 17 | 0 | 2.3 | 12.7 | 28 days |
| AL | 2014-2014 | 1 | 3.4 | 3.4 | 3.4 | 42 days |
| AS+AQ | 2005-2011 | 19 | 0 | 0 | 13.7 | 28 days |
